Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744020 | 0.84 | CYP1A2 (0.37) | CYP1A2POLBCYP2D6TSHRCYP2C19 | |
| SCHEMBL12690466 | 0.81 | CYP1A2 (0.38) | CYP1A2POLBCYP2D6TSHRCYP2C19 | |
| SCHEMBL12537497 | 0.81 | — | — | |
| SCHEMBL1742923 | 0.79 | CNR1 (0.41) | — | |
| SCHEMBL1742965 | 0.78 | CNR1 (0.43) | — | |
| SCHEMBL1742135 | 0.75 | CNR1 (0.45) | — | |
| SCHEMBL12543992 | 0.74 | PSMB1 (0.40) | CYP2D6 | |
| SCHEMBL1742969 | 0.73 | CNR1 (0.38) | POLB | |
| SCHEMBL1742613 | 0.73 | CNR1 (0.38) | POLB | |
| SCHEMBL12544691 | 0.72 | PSMB1 (0.38) | POLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| EP-2470547-B1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2470547-B1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-8481042-B2 | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481042-B2 | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| EP-2598507-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20120244172-A1 | Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120244172-A1 | Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| EP-2470547-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI (FR) | 2012-07-04 | — | — | EP | disclosed |
| WO-2012014147-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012014147-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011023883-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023883-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244172-A1 | Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | GABRA4, GABRA1, GABRA2 | CYP1A2 332/4885POLB 1703/4885CYP2D6 143/4885 |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | GABRA4, GABRP, GABRA1 | CYP1A2 210/4885POLB 1144/4885CYP2D6 73/4885 |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MCL1, TP53, MYC | CYP1A2 1018/4885POLB 1182/4885CYP2D6 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.